GALECTIN THERAPEUTICS INC (GALT) SEC Filings & Earnings Calls

Dilution from authorized share increase

“To adopt and approve an amendment to our Restated Articles of Incorporation increasing the number of authorized common voting shares (“common stock”) from 150,000,000 to 250,000,000.” · word for word

Concentrated ownership and control by Chairman

“Richard E. Uihlein, the Company’s Chairman of the Board and largest stockholder, has provided the Company with various credit facilities to finance the Company’s working capital needs.” · word for word

Going concern uncertainty

“These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of this Form 10-Q.” · word for word

Dependence on financing

“We will require more cash to fund our operations after June 2027. There can be no assurance that we will be successful in obtaining such new financing or, if available, that such financing will be on terms favorable to us.” · word for word

Clinical trial risk; Phase 3 trial not yet initiated.

“Registrational Phase 3 trial protocol submission for belapectin is anticipated in 3Q 2026.” · word for word

Cash burn risk; cash runway only through June 2027.

“The Company believes it has sufficient cash to fund currently planned operations and research and development activities through June 2027.” · word for word

Concentrated ownership risk

“Richard E. Uihlein holds 49.3% beneficial ownership, giving significant control.”

Insider control concentration risk: Chairman's voting power increases to ~49%, potentially enabling unilateral decisions.

“Mr. Uihlein beneficially owns approximately 44.3% of the outstanding voting power on an actual basis and approximately 49.3% of the outstanding voting power” · word for word

Dilution risk: Existing shareholders face ~52% dilution from this single transaction.

“issued 34,376,167 shares ... Company has approximately 100,849,644 shares of Common Stock”

Future registration risk: Shares are unregistered and subject to resale restrictions, but registration rights may lead to future selling pressure.

“Company is obligated to register the resale of such shares within 180 days of the conversion date” · word for word

Concentrated ownership risk

“Richard E. Uihlein holds 49.3% beneficial ownership, giving significant control.”

Execution risk remains for Phase 3 trial enrollment and eventual approval.

“Company intends to file the Phase 3 protocol in Q3 2026 and is actively exploring strategic and financial partnership opportunities” · word for word

Clinical trial failure risk

“In the intent-to-treat (ITT) population (N=355), while the incidence of varices was 43.2% reduced ... the composite endpoint did not reach statistical significance.” · word for word

Dependence on financing from chairman

“our dependence on Mr. Uihlein for financing” · word for word

No approved products / revenue

“we have incurred significant operating losses since our inception and cannot assure you that we will generate revenue or profit” · word for word

Regulatory uncertainty

“we are subject to extensive and costly regulation by the U.S. Food and Drug Administration (FDA)” · word for word

Belapectin still in clinical development; no approved product or revenue. Regulatory and commercial uncertainty remains high.

“No revenue-generating products; cash burn continues; FDA meeting outcome uncertain.”

Cash runway only through May 2027; may require additional financing if development timeline extends.

“The Company believes it has sufficient cash to fund currently planned operations and research and development activities through May 2027.” · word for word

Clinical and regulatory risks for belapectin in MASH cirrhosis; NAVIGATE trial did not meet primary endpoint with statistical significance

“Composite endpoint did not reach statistical significance in ITT population; per-protocol results nominal p=0.04.”

Cash burn risk with limited revenue; reliance on line of credit and potential financing

“Cash $17.7M plus $10M line of credit; no approved products generating revenue.”

Going concern risk

“We have from time to time faced substantial doubt about our ability to continue as a going concern.” · word for word

Financing dependency on single individual

“We are significantly dependent on Mr. Uihlein for financing, and there is no assurance that he will continue to provide funding.” · word for word

Clinical trial failure

“The composite endpoint did not reach statistical significance.” · word for word

Clinical trial failure risk

“In the intent-to-treat (ITT) population (N=355), while the incidence of varices was 43.2% reduced in the belapectin 2 mg/kg dose group vs placebo, the composite endpoint did not reach statistical significance.” · word for word

Dependence on future financing

“We will require more cash to fund our operations after June 30, 2026. There can be no assurance that we will be successful in obtaining such new financing” · word for word

Regulatory and clinical development risks remain; FDA feedback on next steps is pending.

“We submitted the NAVIGATE data package to the FDA and requested feedback on proposed next steps, with guidance anticipated by year-end.” · word for word